{"id":266805,"date":"2024-06-05T00:00:00","date_gmt":"2024-06-05T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0014-2024-biopharma-bladder-cancer-and-upper-tract-urothelial\/"},"modified":"2026-03-31T10:29:48","modified_gmt":"2026-03-31T10:29:48","slug":"cutron0014-2024-biopharma-bladder-cancer-and-upper-tract-urothelial-carcinoma-current-treatment-current-treatment","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0014-2024-biopharma-bladder-cancer-and-upper-tract-urothelial-carcinoma-current-treatment-current-treatment\/","title":{"rendered":"Bladder Cancer and Upper Tract Urothelial Carcinoma &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Bladder Cancer and Upper Tract Urothelial Carcinoma (US)"},"content":{"rendered":"<p class=\"text-align-left\">Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer and upper tract urothelial carcinoma (<abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>). Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo, once limited to locally advanced or metastatic disease, have moved to the resectable stages with the approval of Keytruda for high-risk non-muscle-invasive bladder cancer (<abbr title=\"non-muscle-invasive bladder cancer\">NMIBC<\/abbr>) in 2020 and Opdivo in the adjuvant setting for urothelial carcinoma in 2022. Merck KGaA \/ Pfizer\u2019s Bavencio is entrenched as first-line maintenance treatment following platinum-containing chemotherapy. The combination of Keytruda plus Pfizer \/ Astella\u2019s <abbr title=\"antibody drug conjugate\">ADC<\/abbr> Padcev is now available in the United States for the first-line treatment of locally advanced or metastatic disease, in addition to the drugs&#8217; approval for later-line treatment as monotherapies. The approval of novel therapies (e.g., UroGen Pharma\u2019s Jelmyto, a mitomycin intravesical solution for low-grade <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>; Ferring\u2019s viral vector therapy Adstiladrin for low-grade <abbr title=\"bacillus Calmette-Gu\u00e9rin\">BCG<\/abbr>-unresponsive <abbr title=\"non-muscle-invasive bladder cancer\">NMIBC<\/abbr>; Johnson &#038; Johnson\u2019s first-in-class <abbr title=\"fibroblast growth factor receptor\">FGFR<\/abbr> inhibitor Balversa for previously treated metastatic patients with <abbr title=\"fibroblast growth factor receptor 3\">FGFR3<\/abbr> genetic alterations; Gilead Sciences\u2019 <abbr title=\"antibody drug conjugate\">ADC<\/abbr> Trodelvy for later-line treatment) has greatly expanded physicians\u2019 armamentarium and is reshaping the treatment paradigm.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do drug-treatment rates vary across key patient populations and treatment lines?<\/li>\n<li>What is the uptake of key immune checkpoint inhibitors in the United States across therapy lines? How are immune checkpoint inhibitors faring against older (e.g., platinum-based chemotherapy) and newer therapies (e.g., Balversa, Padcev, Trodelvy)?<\/li>\n<li>Which clinical factors drive the prescribing of a first-line therapy (e.g., chemotherapy plus Bavencio maintenance therapy, Padcev plus Keytruda)? How are treatment lines strategized in locally advanced or metastatic disease?<\/li>\n<li>What are the main drivers of and obstacles to treatment with key drugs for unresectable locally advanced or metastatic urothelial carcinomas (i.e., bladder and\/or upper tract)?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights ontreatment dynamics, prescribing behavior, and drivers of brand useso that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 100 medical oncologists and urologists in the United States fielded in April 2024.<\/p>\n<p><strong>Key drugs: <\/strong>Adstiladrin, Balversa, Bavencio, Jelmyto, Keytruda, Opdivo, Padcev, Trodelvy<\/p>\n","protected":false},"template":"","class_list":["post-266805","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/266805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/266805\/revisions"}],"predecessor-version":[{"id":575954,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/266805\/revisions\/575954"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=266805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}